According to the intelligence financial APP, Nygod New Bright-B (01952) rose more than 8%, as of the deadline, up 8.65%, at HK$25.75, with a turnover of 66.0064 million Hong Kong dollars.

On the news front, according to market sources, recently, with the conclusion of the tenth batch of national drug centralized procurement related meetings of the National Drug Joint Procurement Conference organized by the country, the reporting work of the tenth batch of national drug centralized procurement officially started on October 18. It is reported that from the outflow of documents, this national drug centralized procurement includes a total of 263 specifications of 62 varieties, setting a new record for the quantity of national drug centralized procurement compared to previous times.

Previously, Nygod New Bright's performance for the first half of 2024 showed that the company's total revenue in the first half of the year reached RMB 0.302 billion, a significant increase of 158% compared to the second half of 2023, with operating expenses accounting for a significantly reduced proportion of revenue by 249%, reflecting a significant improvement in operational efficiency. The company stated that by the end of 2024, three products are expected to be commercially launched.

Bocom Intl has released a research report stating that sales volume for the first half of the year by Iqah and Nayfekang exceeded expectations and showed significant growth. Looking ahead to the key points from the second half of 2024 to 2025: the negotiation results of Nayfekang's medical insurance at the end of the year, as well as the continued increase in sales volume of Nayfekang and Iqah; submitting the NDA for Iqumode in mainland China by the end of the year, while starting commercialization in Macau, initiating the listing application for cephalosporin-Tanibantan in China in 2025. The company expects to have 7 commercialized innovative pharmaceutical varieties by 2026.